Capricor Therapeutics (CAPR) Misses Q1 EPS by 2c, Slight Miss on Revenues

Capricor Therapeutics (NASDAQ: CAPR) reported Q1 EPS of ($0.17), $0.02 worse than the analyst estimate of ($0.15). Revenue for the quarter came in at $880.81 thousand versus the consensus estimate of $900 thousand.

For earnings history and earnings-related data on Capricor Therapeutics (CAPR) click here.

You May Also Be Interested In

• These Biotech Breakouts and Squeeze Setups Could Be Just Getting Started
• Hydrofarm Holdings Group, Inc. (HYFM) Misses Q2 EPS by 134c
• Reading (RDI) Tops Q2 EPS by 4c